The burgeoning field of obesity management has witnessed remarkable advancements with the emergence of dual GLP-3 receptor agonists, notably Retatrutide and Trizepatide. These novel therapies represent a significant https://kiarabdmw340741.dailyhitblog.com/44257904/glp-3-receptor-agonists-retatrutide-trizepatide